The essential role of Advocacy in advancing T1D cell therapies
Breakthrough T1D's Advocacy efforts contribute to clear and efficient policies and secure government funding for manufactured cell therapies.
Celiac Disease and Type 1 Diabetes: What’s the Connection?
What is the link between celiac disease and type 1 diabetes? Learn what celiac disease is, how it is treated, and its connection to T1D.
Medical Affairs team kicks off international islet cell therapy workshops at Breakthrough T1D HQ
Breakthrough T1D's Medical Affairs team hosted experts in islet transplantation to discuss a clinical roadmap for manufactured cell therapies.
New Breakthrough T1D publications highlight unmet needs and demographics of the T1D population
Breakthrough T1D recently published two peer-reviewed journal articles. One detailed burdensome unmet needs in the T1D community and identified key steps we can take to meet these needs. The other used real-world data to better understand American T1D demographics and predict changes in the next decade.
Menstrual Cycles, Hormones, and T1D: What Women Need to Know
Menstrual cycles and type 1 diabetes (T1D) have a lot in common: they can be unpredictable, inconsistent from person to person, and physically challenging. Let’s take a closer look at how periods and menopause may influence blood sugar. What happens during the menstrual cycle? Most girls get their first period around age 12. Then, each […]
Treating and preventing eye disease with type 1 diabetes
Diabetic eye disease is a troubling reality for many people living with type 1 diabetes, but research is helping reduce the risk of complications.
Cell therapies in clinical trials: Moving the needle forward
Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how we’re going to make them a reality.
From unexpected diagnosis to DIAGNODE-3 participant
Katie Howell was diagnosed with type 1 diabetes last year at age 25. Now, she's the first DIAGNODE-3 trial participant in NYC.
ATTD 2025: Closing the loop to cures
At ATTD 2025, Breakthrough T1D led sessions showcasing advancements in T1D cell therapies, early detection, and technology to improve lives.
From Breakthrough T1D trainee to Principal Investigator: Kelsey Voss, Ph.D., is calling the shots
Kelsey Voss, Ph.D., received Breakthrough T1D's Advanced Postdoctoral Fellowship Award, which helped start her lab at UVA studying T cells in type 1 diabetes.
